User menu

Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response

Bibliographic reference Delwaide, J. ; Bourgeois, N. ; Gerard, C ; De Maeght, S ; Mokaddem, F ; et. al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. In: Alimentary Pharmacology and Therapeutics, Vol. 20, no. 1, p. 15-22 (2004)
Permanent URL
  1. BARRERA J, Persistent Hepatitis C viremia after acute self-limiting posttransfusion Hepatitis C, 10.1016/0270-9139(95)90511-1
  2. Seeff L, Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study, 10.1053/jhep.2001.21905
  3. Thomas D, JAMA, 284, 45 (2000)
  4. Villano Stephen A., Vlahov David, Nelson Kenrad E., Cohn Sylvia, Thomas David L., Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection, 10.1002/hep.510290311
  5. Santantonio T, Dig Liver Dis, 35, 104 (2003)
  6. Rodger Alison J., Roberts Stuart, Lanigan Anna, Bowden Scott, Brown Tracy, Crofts Nick, Assessment of Long-Term Outcomes of Community-Acquired Hepatitis C Infection in a Cohort With Sera Stored From 1971 to 1975, 10.1053/jhep.2000.9714
  7. Gerlach J.Tilman, Diepolder Helmut M, Zachoval Reinhart, Gruener Norbert H, Jung Maria-Christina, Ulsenheimer Axel, Schraut Winfried W, Schirren C.albrecht, Waechtler M, Backmund M, Pape Gerd R, Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication., 10.1016/s0016-5085(03)00668-1
  8. Kenny-Walsh Elizabeth, Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin, 10.1056/nejm199904223401602
  9. Gerlach TJ, Hepatology, 34, 341A (2001)
  10. Alric L., Fort M., Izopet J., Vinel J.-P., Bureau C., Sandre K., Charlet J.-P., Beraud M., Abbal M., Duffaut M., Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance, 10.1034/j.1399-0039.2000.560207.x
  11. Vogt Manfred, Lang Thomas, Frösner Gert, Klingler Christiane, Sendl Anna F., Zeller Anita, Wiebecke Baldur, Langer Barbara, Meisner Hans, Hess John, Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening, 10.1056/nejm199909163411202
  12. Alberti Alfredo, Boccato Silvia, Vario Alessandro, Benvegnù Luisa, Therapy of acute hepatitis C : Therapy of acute hepatitis C, 10.1053/jhep.2002.36808
  13. Hoofnagle Jay H., Therapy for Acute Hepatitis C, 10.1056/nejm200111153452013
  14. Takano Susumu, Satomura Yoichi, Omata Masao, Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study, 10.1016/0016-5085(94)90130-9
  15. Licata Anna, Di Bona Danilo, Schepis Filippo, Shahied Lillian, Craxı̀ Antonio, Cammà Calogero, When and how to treat acute hepatitis C?, 10.1016/s0168-8278(03)00461-6
  16. Delwaide J, Hepatology, 30, 264 (1999)
  17. Jaeckel Elmar, Cornberg Markus, Wedemeyer Heiner, Santantonio Teresa, Mayer Julika, Zankel Myrga, Pastore Giuseppe, Dietrich Manfred, Trautwein Christian, Manns Michael P., Treatment of Acute Hepatitis C with Interferon Alfa-2b, 10.1056/nejmoa011232
  18. Vogel W, Dig Dis Sci, 41, 81S (1996)
  19. Royer Cathy, Steffan Anne-Marie, Navas Maria-Cristina, Fuchs Anne, Jaeck Daniel, Stoll-Keller Françoise, A study of susceptibility of primary human Kupffer cells to hepatitis C virus, 10.1016/s0168-8278(02)00418-x
  20. Hofer H, Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load, 10.1053/jhep.2003.50019